Six months of treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) significantly improved lung function and nutritional status in two adults with…
Articles by Andrea Lobo, PhD
The pediatric and adult cystic fibrosis programs at Geisinger Medical Center have received an award from the Cystic Fibrosis…
Kaftrio and Symkevi — marketed in the U.S. as Trikafta and Symdeko, respectively — may be effective in…
Treatment with Kaftrio eased gastrointestinal symptoms in people with cystic fibrosis (CF), ages 12 and older, according to…
Electronic home monitoring using a spirometry device may help improve lung function in children with cystic fibrosis (CF), according…
Almost two years of treatment with Kaftrio (elexacaftor, tezacaftor, and ivacaftor) did not affect liver stiffness — an indicator…
Inogen has acquired Physio-Assist, including Simeox, a technology for airway clearance and mucus management in people with…
Infections with Staphylococcus aureus small colony variants, known as SCVs, are highly prevalent in people with cystic fibrosis (CF) —…
An increase in body mass index (BMI) in people with cystic fibrosis (CF) under Kaftrio therapy may not…
Anxiety and depression are more likely in younger cystic fibrosis (CF) patients with CF-related diabetes and more evident…